Barclays Maintains Buy Rating and $383 PT on Cigna (CI)

The Cigna Group (NYSE:CI) is one of the most undervalued large cap stocks to buy right now. On October 28, Andrew Mok CFA from Barclays maintained a Buy rating on Cigna, with a price target of $383.00.

Earlier on October 14, Goldman Sachs analyst Scott Fidel initiated coverage of Cigna with a Buy rating and $370 price target. The firm noted that the managed care industry is currently experiencing its most substantial underwriting downturn in over 15 years and recommends investors increase their exposure to the Medicare Advantage segment, projecting that a margin recovery phase will begin in 2026.Barclays Maintains Buy Rating and $383 PT on Cigna (CI)

In other news, on October 27, Evernorth, the health services division of The Cigna Group, announced a new era of pharmacy benefit services to lower Americans’ medication costs, improve transparency, and better support local pharmacies. This initiative follows an earlier call by President Trump to address high brand-name drug costs and builds on Evernorth’s track record of innovation, which has already helped the US achieve the lowest prices for generics, which account for 90% of all prescriptions.

The Cigna Group (NYSE:CI), together with its subsidiaries, provides insurance and related products and services in the US.

While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments